Brian Madden AbbVie Inc. ABBV-N BUY May 10, 2024

Abbvie is famous for Humira, now off-patent. They've done well filling that hole, but their growth rate is now tepid. So, he sold it.

Have a great drug pipeline.

Management has replaced key drug, Humira, and made key acquisitions. Are doing all the right things.

They beat top and bottom and raised guidance. A nice quarter. Their key drugs were way up. They have a strong pipeline.

Is one of the largest companies in bio-medicals. Growth has been impressive. Are expanding into neuro-science, Alzheimer's. They clearly replaced a key drug going off-patent with a good pipeline. Two anti-inflammatory drugs are outperforming expectations.

He added more AbbVie. Obviously, today's news about the disappointing drug trials is not good. This schizophrenia drug was projected to make $1.1 billion in sales four years from now. But today's share plunge is too great, overdone. He might add on even more weakness. Trades at 14x forward PE and pays a 3.9% dividend. It's a great company on sale. They have a long track record of making acquisitions.

The drug companies are in the dog house. If you buy this, you must be patient. It yields 4%.

It is a large cap biotech with a temporary pullback. Humera went off patent so there are some declines in revenue. He really likes the re-iteration of Humera which has taken off. Also it is re-designing a mistrial.          Buy 20  Hold 10  Sell 0

His best performer so far this year, up 12%. Well-managed. They replaced Humira with hit drugs and added key companies; pays a 3.2% dividend. 

Skyrizi continues to work.